Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Assets Average (2016 - 2025)

CytomX Therapeutics' Assets Average history spans 11 years, with the latest figure at $154.9 million for Q4 2025.

  • For Q4 2025, Assets Average rose 19.38% year-over-year to $154.9 million; the TTM value through Dec 2025 reached $154.9 million, up 19.38%, while the annual FY2025 figure was $136.0 million, 15.58% down from the prior year.
  • Assets Average reached $154.9 million in Q4 2025 per CTMX's latest filing, down from $166.7 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $418.3 million in Q2 2021 to a low of $109.5 million in Q1 2025.
  • Average Assets Average over 5 years is $237.4 million, with a median of $218.5 million recorded in 2023.
  • The largest YoY upside for Assets Average was 19.38% in 2025 against a maximum downside of 43.33% in 2025.
  • A 5-year view of Assets Average shows it stood at $355.3 million in 2021, then crashed by 31.42% to $243.7 million in 2022, then fell by 13.22% to $211.5 million in 2023, then plummeted by 38.64% to $129.8 million in 2024, then increased by 19.38% to $154.9 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Assets Average are $154.9 million (Q4 2025), $166.7 million (Q3 2025), and $136.8 million (Q2 2025).